- Home
- EVOK vs VIVS Comparison
EVOK vs VIVS Comparison
Compare EVOK & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- VIVS
- Stock Information
- Founded
- EVOK 2007
- VIVS 2007
- Country
- EVOK United States
- VIVS United States
- Employees
- EVOK N/A
- VIVS N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVOK Health Care
- VIVS Health Care
- Exchange
- EVOK Nasdaq
- VIVS Nasdaq
- Market Cap
- EVOK 4.2M
- VIVS 4.2M
- IPO Year
- EVOK 2013
- VIVS N/A
- Fundamental
- Price
- EVOK $2.65
- VIVS $1.45
- Analyst Decision
- EVOK
- VIVS
- Analyst Count
- EVOK 0
- VIVS 0
- Target Price
- EVOK N/A
- VIVS N/A
- AVG Volume (30 Days)
- EVOK 18.7K
- VIVS 64.3K
- Earning Date
- EVOK 08-12-2025
- VIVS 07-07-2025
- Dividend Yield
- EVOK N/A
- VIVS N/A
- EPS Growth
- EVOK N/A
- VIVS N/A
- EPS
- EVOK N/A
- VIVS N/A
- Revenue
- EVOK $11,594,083.00
- VIVS $144,000.00
- Revenue This Year
- EVOK $57.82
- VIVS $42.38
- Revenue Next Year
- EVOK $59.12
- VIVS $15.42
- P/E Ratio
- EVOK N/A
- VIVS N/A
- Revenue Growth
- EVOK 89.89
- VIVS 32.11
- 52 Week Low
- EVOK $1.94
- VIVS $1.41
- 52 Week High
- EVOK $12.32
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- EVOK 39.39
- VIVS N/A
- Support Level
- EVOK $2.46
- VIVS N/A
- Resistance Level
- EVOK $2.84
- VIVS N/A
- Average True Range (ATR)
- EVOK 0.28
- VIVS 0.00
- MACD
- EVOK -0.05
- VIVS 0.00
- Stochastic Oscillator
- EVOK 15.40
- VIVS 0.00
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.